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Cyclo-oxygenase inhibition reduces tumour growth and
metastasis in an orthotopic model of breast cancer
EM Connolly1,3, JH Harmey*,1,3, T O’Grady2, D Foley1, G Roche-Nagle1, E Kay2 and DJ Bouchier-Hayes1
1Department of Surgery, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland; 2Department of
Pathology, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland
The effect of selective and non-selective cyclo-oxygenase inhibition on tumour growth and metastasis in an orthotopic model
of breast cancer was investigated. 4T1 mammary adenocarcinoma cells were injected into the mammary fat pad of female
BALB/c mice. When tumours reached a mean tumour diameter of 8.4+0.4 mm, mice were randomised into three groups
(n=6 per group) and received daily intraperitoneal injections of the selective cyclo-oxygenase-2 inhibitor, SC-236, the non
selective cyclo-oxygenase inhibitor, Indomethacin, or drug vehicle. Tumour diameter was recorded on alternate days. From 8
days after initiation of treatment, tumour diameter in animals treated with either SC-236 or indomethacin was significantly
reduced relative to controls. Both primary tumour weight and the number of lung metastases were significantly reduced in the
SC-236 and indomethacin treated mice. Microvessel density was reduced and tumor cell apoptosis increased in the primary
tumour of mice treated with either the selective or non-selective cyclo-oxygenase inhibitor. In vitro, cyclo-oxygenase inhibition
decreased vascular endothelial growth factor production and increased apoptosis of tumour cells. Our results suggest that
cyclo-oxygenase inhibitors will be of value in the treatment of both primary and metastatic breast cancer.
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Breast cancer is the commonest malignancy in women. Despite the
introduction of breast screening and multimodal treatment with
surgery, chemotherapy and radiotherapy over 14 000 women die
every year in Britain from breast cancer (McPherson et al, 2000).
Angiogenesis, the formation of new capillaries from pre-existing
blood vessels, is essential for the growth and metastasis of solid
tumours (Folkman, 1990; Fidler and Ellis, 1994). High levels of
angiogenesis within the primary tumour are associated with
increased metastasis, as the new vessels allow tumour cells access
to the circulation facilitating tumour dissemination (Anan et al,
1996). Angiogenesis is of particular importance in breast cancer
where the switch to the angiogenic phenotype occurs at the pre-
invasive ductal carcinoma in situ phase (Zolota et al, 1999). Micro-
vessel density within the primary tumour, a measure of the degree
of angiogenesis, is an independent predictor of metastatic disease
in breast cancer (De Jong et al, 2000). Vascular endothelial growth
factor (VEGF) is a potent pro-angiogenic cytokine (Peters et al,
1993) and increases vascular permeability, resulting in leaky blood
vessels, which facilitates metastasis (Senger et al, 1983). We have
recently demonstrated that VEGF also protects at least some breast
cancer cells from apoptosis (Pidgeon et al, 2001). VEGF is
produced by both host inflammatory cells and tumour cells (Free-
man et al, 1995; Harmey et al, 1998). The level of tumour VEGF is
an independent prognostic factor for survival in breast cancer
(Linderholm et al, 1998).
In addition to new vessel formation, net tumour growth
depends on the balance between tumour cell proliferation and
apoptosis (Holmgren et al, 1995). Apoptosis, or programmed cell
death, is characterised by single-cell death in the midst of living
cells. The relative level of apoptosis and proliferation determines
tumour growth, and any alteration in either process is a key
element for determining tumour size (Fisher, 1994).
Prostaglandins are implicated in the development and growth of
malignant tumours (Taketo, 1998). Cyclo-oxygenase (COX), the
key regulatory enzyme for prostaglandin synthesis, is transcribed
from two distinct genes. COX-1 is expressed constitutively in most
tissues whereas COX-2 is rapidly induced at sites of inflammation
and at sites of proliferation, for example within tumours (Bjork-
man, 1998; Hawkey, 1999; Soslow et al, 2000). Non-steroidal
anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase enzymes
and consequently can inhibit, or abolish the effects of prostaglan-
dins (Bjorkman, 1998; Hawkey, 1999). Increasing evidence shows
that NSAIDs can inhibit tumour growth in experimental animals
and in humans (Taketo, 1998; Milas, 1999). Commonly used
NSAIDS, such as indomethacin, inhibit both COX-1 and COX-2
but treatment with such agents may be limited by toxicity to
normal tissues, particularly ulceration and bleeding in the gastroin-
testinal tract as a consequence of COX-1 inhibition (Milas et al,
1999 and refs therein). Recently developed selective COX-2 inhibi-
tors, for example celecoxib, exert potent anti-inflammatory activity
but cause fewer unwanted side effects (Bjorkman, 1998; Hawkey,
1999). Selective COX-2 inhibitors have been shown to prevent
carcinogenesis in experimental models of colon cancer (Reddy et
al, 2000) and chemically-induced breast cancer (Harris et al,
2000). The possible mechanism of anti-tumour effects of COX
inhibitors may be due to inhibition of angiogenesis (Tsujii et al,
1998) or induction of apoptosis (Li et al, 2001).
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In this study the anti-tumour effects of a selective COX-2 inhi-
bitor, SC-236, and the non-selective inhibitor, indomethacin were
investigated in an orthotopic model of established breast cancer
(Pulaski and Ostrand-Rosenberg, 1998). The direct effect of COX
inhibition on tumour cell apoptosis and VEGF production in vitro
was evaluated.
MATERIALS AND METHODS
Animals
Female 10- to 12-week old BALB/c mice (Charles River Institute,
Margate, Kent, UK) were used. The animals were acclimatised
for 1 week and caged in groups of five or less in an air conditioned
room at ambient temperature of 21 – 228C and 50% humidity
under a 12-h light-dark cycle (lights at 08.00). Animals were
housed in a licensed biomedical facility (RCSI Department of
Surgery, Beaumont Hospital) and all procedures were carried out
under animal license guidelines of the Department of Health,
Ireland and in accordance with the UK Co-ordinating Committee
on Cancer Research (UKCCR) Guidelines for the Welfare of
Animals in Experimental Neoplasia. Animals had ad libitum access
to animal chow (WM Connolly & Sons Ltd, Kilkenny, Ireland) and
water.
Tumour cells and culture conditions
4T1 tumour cells, a spontaneously metastasising mammary adeno-
carcinoma cell line were a generous gift from Dr Fred Miller, Duke
University. Cells were maintained as monolayer cultures in Dulbec-
co’s Modified Eagle Medium supplemented with 10% foetal bovine
serum, sodium pyruvate, non-essential amino acids, L-glutamine
and vitamins (Life Technologies, Inc., GIBCO – BRL, Paisley, UK)
in an atmosphere of 5% CO2 in air at 378C. Tumour cells were
harvested from subconfluent cultures with 0.25% Trypsin-0.02%
EDTA. Trypsin was neutralised with medium containing 10%
FBS, washed three times in phosphate buffered saline (PBS) and
resuspended in PBS at 56105 ml71 for injection. Only single cell
suspensions of greater than 90% viability as determined by Trypan
blue exclusion were used for injections.
Experimental design
Five6104 (100 ml) 4T1 cells were injected into the mammary fat
pad adjacent to the left forefoot after anaesthesia was induced and
maintained with inhalational halothane. Primary tumours were
measured on alternate days following injection of tumour cells using
Vernier calipers. Tumour diameter (TD) was calculated as the
square root of the product of two perpendicular diameters (Pulaski
and Ostrand-Rosenberg, 1998). When mean TD was 8.4+0.4 mm
(day 12 post injection of tumour cells), at which time micrometas-
tases are already present in the lungs, mice were randomised into
one of three groups (n=6 per group) to receive daily intraperitoneal
injections of 200 ml vehicle (1% v v71 dimethylsulphoxide
[DMSO]), the selective COX-2 inhibitor, SC-236 (kind gift from
Dr P Isakson, Monsanto, St Louis, MI, USA), (6 mg kg71 in 1%
DMSO) or the non-selective COX inhibitor, indomethacin
(3 mg kg71 in 1% DMSO). These doses were selected based on
previously published studies (Milas et al, 1999), pilot studies and
known toxicity of indomethacin. Tumour diameters were measured
on alternate days. Thirteen days after initiation of drug treatment
when the mean TD in the control group was 17 mm, all animals
were euthanased. Primary tumours were excised, fixed in 10%
formalin and processed for histology. Lungs were excised, fixed in
Bouins solution and the number of lung lesions determined with
the aid of a dissecting microscope (Yano et al, 2000).
At the time of sacrifice animals were anaesthesised with
halothane and exsanguinated via closed cardiac puncture. Blood
was allowed to clot for 2 h at room temperature and centrifuged
for 20 min at 1100 g. Serum was removed, filtered through a
0.22 mm filter and stored at – 808C. VEGF was measured by
enzyme-linked immunosorbent assay (ELISA) according to manu-
facturer’s instructions (R&D Systems, Oxford, UK).
Quantification of microvessel density
Paraffin embedded tissue sections (4 mm) were deparaffinised in
xylene, rehydrated in graded alcohol, and transferred to PBS.
Sections were washed twice with PBS, and endogenous peroxidase
activity was blocked by incubating slides with 3% hydrogen perox-
ide in methanol. Sections were washed in PBS and incubated in
blocking solution (5% normal rabbit serum in PBS) for 30 min.
Excess blocking solution was aspirated and sections were incubated
for 90 min at room temperature with 1 : 100 dilution of monoclo-
nal goat anti CD31 (PECAM1-M20) (Santa Cruz, Biotech, Santa
Cruz, CA, USA). Sections were washed with PBS followed by
blocking solution for 10 min. Sections were washed with PBS
and incubated with secondary antibody according to the manufac-
turer’s instructions (Vectastain anti-goat kit, Vector labs). Bound
antibody complexes were visualised using 3,3’-diaminobenzidine
(DAB). Sections were counterstained with haematoxylin, dehy-
drated through graded alcohols, cleared with xylene and
mounted in DPX mounting media.
For each section, vessels were counted in five high power fields
(2006magnification (620 objective and 610 ocular)) as
described (Xu et al, 2000). Data is expressed as mean+s.e.m.
Tumour apoptosis and proliferation
Apoptotic cells in formalin fixed, paraffin-embedded breast tumour
sections (4 mm), were stained using the in situ cell death detection
kit according to the manufacturer’s instructions (Boehringer
Mannheim, East Sussex, UK). Peroxidase activity was visualised
by the precipitation of DAB and sections were lightly counter-
stained with haematoxylin. Apoptotic cells stained brown against
a blue background. Only cells that stained brown and had the
morphological appearance of an apoptotic cell were counted as
apoptotic cells, necrotic cells were easily distinguished and were
excluded. Apoptosis was expressed as the number of positively
stained cells in five high power fields per section (4006magnifica-
tion (640 objective and 610 ocular)).
Proliferation in primary tumours was assessed following staining
for proliferation cell nuclear antigen (PCNA). Four mm paraffin
embedded sections were dewaxed in xylene, rehydrated in graded
alcohols and washed in Tris-buffered saline (TBS) (25 mM Tris-
HCl, pH 7.6, 150 mM NaCl) before blocking endogenous peroxi-
dase activity in 3% hydrogen peroxide in methanol. Antigen
retrieval was carried out by microwave treatment of sections in
10 mM trisodium citrate (pH 6.0) for 20 min. Sections were
washed in TBS before incubation with mouse monoclonal anti-
PCNA antibody (DAKO, Denmark) diluted 1 : 800 in TBS at room
temperature for 40 min. Sections were washed in TBS and incu-
bated with biotinylated goat anti mouse/rabbit immunoglobulins
according to the manufacturer’s instructions (StreptABComplex/
HRP Duet kit [DAKO Corporation, Denmark]). Antibody
complexes were visualised with DAB. Sections were counterstained
with haematoxylin, dehydrated through graded alcohols, cleared
with xylene and mounted in DPX mounting media. The percentage
proliferation was calculated by counting the number of PCNA
positive and PCNA negative cells in three high power fields per
section (4006magnification (640 objective and 610 ocular)).
In vitro experiments
VEGF production Five6103 4T1 cells were plated at 56103/well
in 96 well plates. 16 h later, SC-236 or indomethacin (5 or 10 mM
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each) were added for 24 h. Culture supernatants were collected and
VEGF measured by ELISA (R&D Systems, UK). Cells were washed
twice with PBS and total protein measured using the Bicinchonic Acid
method (Pierce, IL, USA). VEGF was expressed as pg VEGF mg71 cell
protein. Each experiment was carried out three times in triplicate.
Apoptosis Five6104 4T1 cells were plated on plastic culture
chamber slides (LabTekTMPermanox Chamber slides, Nalge Nunc
International). Sixteen hours later SC-236 or indomethacin (5 or
10 mM each) were added for 24 h. Cells were fixed and stained
using in situ cell death detection kit (Boehringer Mannheim, East
Sussex, UK). The percentage of apoptotic cells per high power field
(4006magnification (640 objective and 610 ocular)) was
recorded in each of three fields per sample. Each experiment was
carried out three times in triplicate.
Statistical analysis
Data are expressed as mean+standard error mean (s.e.m.). Differ-
ences between in vivo and in vitro treatment groups were
determined by one way ANOVA with Tukey Kramer post-hoc test
using Instat for Windows statistics package (Graphpad Software
Inc). Data were taken as significant where P50.05.
RESULTS
Effect of COX inhibition on primary tumour growth and
metastasis
4TI mammary adenocarcinoma cells spontaneously metastasise to
the lungs from the mammary fat pad (Pulaski and Ostrand-Rosen-
berg, 1998). Following implantation of tumour cells into the
mammary fat pad, tumour diameter (TD) was measured on alter-
nate days. When mean TD was 8.4+0.4 mm, at which time
micrometastases are already present in the lungs, treatment with
6 mg kg71 SC-236 (15.6 mM) or 3 mg kg71 indomethacin
(8.3 mM) was initiated. These doses were based on pilot studies
and previously published doses (Milas et al, 1999). Although
3 mg kg71 indomethacin has previously been found to be toxic
when administered by gavage (Masferrer et al, 2000), we did not
observe any toxicity using intra-peritoneal delivery. From 8 days
after treatment until the end of the experiment, there was a signifi-
cant difference in primary tumour growth in the SC-236-treated and
indomethacin-treated mice relative to untreated control mice. There
was no significant difference in TD of mice treated with either the
selective COX-2 inhibitor, SC-236 (6 mg kg71), or the non-selective
COX inhibitor, indomethacin (3 mg kg71) (Figure 1). Neither drug
regime caused regression of the established tumours but rather
inhibited further tumour growth. Thirteen days after treatment
was initiated, there was a significant reduction (P50.05) in primary
tumour size in both SC-236 treated (11.8+1.3 mm) and indo-
methacin treated mice (11.2+0.7 mm) relative to control
(17.0+1.1 mm) (Table 1). There was no significant difference in
tumour size between SC-236 and indomethacin treated groups.
Both SC-236 and indomethacin treatment resulted in a signifi-
cant reduction in the number of spontaneous lung metastases
relative to untreated controls (Table 1). Pleural effusions were
present in two of the control mice whereas none of the mice in
the treatment groups had evidence of pleural effusions (Table 1).
The effects of COX inhibition on primary tumour growth and
metastasis were confirmed in a second experiment (n=5 per group,
data not shown).
Effect of COX inhibitors on proliferation and apoptosis
within the primary tumour
The relative levels of apoptosis and cell proliferation determine net
tumour growth. As both the selective and non-selective COX inhi-
bitors significantly reduced primary tumour growth we investigated
the effects of COX inhibition on apoptosis and proliferation within
the tumour. Proliferating cells were identified by PCNA staining
and apoptosis by TUNEL staining. Representative sections stained
for PCNA and apoptotic cells are shown in Figure 2A,B, respec-
tively. Neither treatment had any effect on level of proliferation
within the tumour (Figure 2C). However, both SC-236
(12.75+0.98 apoptotic cells per h.p.f.) and indomethacin
(16.1+1.3 apoptotic cells per h.p.f.) treatment results in a signifi-
cant increase in the level of apoptosis relative to control tumours
(7.12+1.6 apoptotic cells per h.p.f.) (Figure 2D) with no signifi-
cant difference between the two treatment groups.
COX inhibition reduces tumour angiogenesis
To further investigate the mechanisms by which treatment with
either a selective COX-2 inhibitor (SC-236) or a non-selective
COX-1 and COX-2 inhibitor (indomethacin) reduced primary
tumour growth and metastasis, we examined the effect of treat-
ment on angiogenesis within the primary tumour.
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Figure 1 Tumour growth curve of mammary fat pad tumours. Twelve
days after implantation of 4TI tumours, mice received daily injections of
SC-236, indomethacin or vehicle for a further 13 days (n=6 per group).
Tumour diameter was recorded on alternate days. Treatment with SC-
236 or indomethacin significantly inhibited tumour growth relative to con-
trols. Data expressed as mean+s.e.m. *P50.05 COX-2 vs control,
#P50.05 indomethacin vs control.
Table 1 Effect of selective COX-2 inhibition (SC-236) and non-selective
COX-1+2 inhibition (indomethacin) on 4TI mammary fat pad tumour
growth and metastasis
Primary Incidence Number of Incidence of
tumour of pulmonary pulmonary pleural
mean TD (mm) metastasis nodules effusion
Control 17+1.1 6/6 17 (6 – 28) 2/6
SC-236 11.8+1.3a 5/6 2 (0 – 21)b 0/6
Indomethacin 11.2+0.7a 5/6 4 (0 – 8)b 0/6
BALB/c female mice were injected with 56104 4T1 cells into the mammary fat pad.
Daily intraperitoneal injections of vehicle, SC-236 or indomethacin began on day 12
and continued for 13 days. The animals were sacrificed. Primary tumours were
weighed, presence or absence of pleural effusion and the number of pulmonary
nodules were recorded. Tumour size is shown as mean+s.e.m. and nodule data
as median (range). Data were analysed using one way ANOVA with Tukey Kramer
post-hoc test, aP=50.001 vs control, b=P=50.05 vs control.
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Vascularisation was identified by staining tumours with an anti-
body to CD31 and the number of vessels per high power field
scored. Representative sections from control, SC-236 treated and
indomethacin treated tumours are shown in Figure 3A – C respec-
tively. Both SC-236 (65.8+3.5 vessels per h.p.f.) and indomethacin
(55.6+2.2 vessels per h.p.f.) treatment significantly reduced angio-
genesis in the primary tumour relative to controls (84+6 vessels
per h.p.f.) (Figure 3D). There was no significant difference in
microvessel density within SC-236 or indomethacin treated
tumours.
Serum VEGF was measured by ELISA (Figure 4). Treatment
with either SC-236 (114+23.6 pg ml71) or indomethacin
(87.2+18.6 pg ml71) significantly reduced circulating VEGF rela-
tive to controls (516.4+215 pg ml71).
Effect of COX inhibition on 4T1 cell apoptosis and VEGF
production in vitro
In vivo, treatment with either indomethacin (8.3 mM) or SC-236
(15.6 mM) resulted in increased apoptosis within primary tumour
and decreased circulating VEGF. We examined the effects of these
compounds on apoptosis and VEGF production by 4T1 cells in
vitro. Treatment with SC-236 (5 mM: 0.77+0.066 pg mg71,
10 mM: 0.74+0.063 pg mg71)or indomethacin (5 mM: 0.71+
0.058 pg mg71, 10 mM: 0.71+0.066 pg mg71), significantly
decreased VEGF production by 4T1 tumour cells relative to control
cells (1.5+0.18 pg mg71) (Figure 5A). There was no significant
difference between SC-236 and indomethacin at either of the doses
studied. Furthermore, when we examined tumour cell apoptosis,
we found that either SC-236 (5 mM: 1.14+0.119%, 10 mM:
1.28+0.090%), or indomethacin (5 mM: 1.19+0.072%, 10 mM:
1.29+0.149%), treatment significantly increased apoptosis at both
5 and 10 mM relative to control cells (0.2+0.059% apoptosis) and
again, there was no difference between the two inhibitors at either
of the doses studied (Figure 5B).
DISCUSSION
Using an orthotopic murine model of breast cancer, cyclo-oxyge-
nase inhibitors reduced primary tumour growth and spontaneous
E
xp
erim
en
tal
T
h
erap
eu
tics
%
 P
CN
A 
po
sit
ive
 c
e
lls
/H
PF
A
B
C
80
70
60
50
40
30
20
10
0
Control SC-236 Indo
TU
NE
L 
po
sit
ive
 c
e
lls
/H
PF
D
20
18
16
14
12
10
8
6
4
2
0
Control SC-236 Indo
Figure 2 Apoptosis and proliferation in 4TI mammary fat pad tumours. (A) PCNA-positive (proliferating) cells within tumours (original magnification
6400). (B) TUNEL-positive (apoptotic) cells within tumours. Apoptotic cells stain brown after TUNEL staining (original magnification6400). (C) % PCNA
positive cells in tumours from control mice and mice treated with SC-236 or indomethacin. Three high power fields per section (4006magnification (640
objective and 610 ocular)). Data represented as mean+s.e.m. P=n.s. (D) Number of TUNEL positive cells per h.p.f. Five high power fields per section
(4006magnification (640 objective and 610 ocular)). SC-236 or indomethacin significantly increased apoptosis relative to tumours from control mice
(one section from each of six mice per group). Data represented as mean+s.e.m. *P50.05.
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metastasis, an effect associated with increased apoptosis and
reduced angiogenesis in the primary tumour.
Although NSAIDs have been shown to reduce the risk of breast
cancer (Sharpe et al, 2000), it is not known how they reduce this
risk nor is it known what effect they have on established breast
cancer. Both selective COX-2 (celecoxib) and non selective COX
inhibition (ibuprofen) reduced the incidence and subsequent
growth of primary breast tumours induced by 7,12-dimethylben-
z(a)anthracene (DMBA) in female Sprague Dawley rats (Alshafie
et al, 2000; Harris et al, 2000). The selective COX-2 inhibitor,
celecoxib, inhibited the growth and metastasis of ectopically
implanted Lewis lung and HT29 colon tumours (Masferrer et
al, 2000). However, it is well established that faithful reproduction
of the tumour microenvironment occurs only in orthotopic
tumour models (Killion et al, 1999; Hoffman, 1999). In this
experiment we used an orthotopic murine model of breast cancer
where 4TI mammary carcinoma cells were injected directly into
the mammary fat pad of female BALB/c mice. 4TI cells originated
from a spontaneously occurring BALB/c mouse breast tumour and
share many characteristics with human mammary cancers, making
it an excellent model of breast cancer (Pulaski and Ostrand-
Rosenberg, 1998). This model also has the advantage of forming
spontaneous metastases and pleural effusions similar to the devel-
opment of malignant pleural effusions in advanced breast cancer
patients. In this model, either the selective COX-2 inhibitor,
SC-236, or the non selective COX inhibitor, indomethacin, inhib-
ited the growth of established tumours. The number of
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Figure 3 Angiogenesis in 4TI mammary fat pad tumours. Representative sections of tumours stained for CD31 from control mice (A), SC-236 treated
(B), and indomethacin treated mice (C) are shown. Original magnification6200. (D) Microvessel density was assessed by light microscopy following CD31
staining (one section from each of six mice per group). For each section, vessels were counted in five high power fields (2006magnification (620 objective
and 610 ocular)). Data is expressed as mean number of vessels per h.p.f.+s.e.m. *P50.05 vs control.
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Figure 4 Serum VEGF levels. Blood was collected by cardiac puncture
and serum VEGF measured by ELISA (n=6 per group). Data is expressed
as mean pg VEGF ml71 serum+s.e.m. Treatment with SC-236 or indo-
methacin significantly reduced VEGF relative to controls. *P50.05.
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spontaneous lung metastases was also significantly reduced follow-
ing either treatment. This reduction in metastasis could be a
consequence of reduced primary tumour size in treated mice
rather than an inhibition of metastasis per se. We are currently
examining the effect of COX inhibitors on the growth of metas-
tases following excision of a primary tumour and in
experimental metastasis models to clarify this issue. It will also
be necessary to examine the efficacy of COX inhibitors in human
orthotopic models.
NSAIDS can induce cells to undergo apoptosis in vitro (Lu et al,
1995). Selective COX-2 inhibition has been shown to induce apop-
tosis through a cytochrome C-dependent pathway in oesophageal
cancer cells (Li et al, 2001). Arachidonic acid, the substrate for
COX, stimulates apoptosis, thus enhanced COX-2 expression could
inhibit apoptosis by decreasing arachidonic acid (Cao et al, 2000).
We found that in vivo, COX inhibition increased apoptosis with no
change in proliferation in the primary tumours relative to control.
Furthermore, COX inhibition in vitro directly increased tumour
cell apoptosis.
Microvessel density within the primary tumour has been shown
to be an independent predictor of metastatic disease in breast
cancer patients (De Jong et al, 2000). COX-2 inhibitors have been
shown to reduce angiogenesis in vitro (Tsujii et al, 1998). Williams
et al (2000) found reduced angiogenesis in Lewis lung carcinomas
grown in COX-2 knockout (COX-27/7) mice when compared to
tumours grown in wild type mice. In our study, inhibition of
primary tumour growth and metastasis in mice treated with
COX inhibitors was associated with a significant reduction in
microvessel density in the primary tumour, suggesting that these
drugs exert their anti-tumour effect, at least in part, by reducing
angiogenesis in the primary tumour. As the degree of tumour
angiogenesis is predictive of metastatic disease (De Jong et al,
2000), the reduction in primary tumour MVD may account for
the reduced number of pulmonary metastases following COX inhi-
bition. We also found reduced serum levels of VEGF in the COX
inhibited groups relative to control. However, we previously
demonstrated that serum VEGF correlates with metastatic burden
in an experimental metastasis model (Pidgeon et al, 1999). Both
the reduction in VEGF and angiogenesis could simply be a reflec-
tion of reduced primary tumour size in treated mice, although in
vitro COX inhibition directly reduced VEGF production by the
4T1 tumour cells used in this study.
These results suggest that COX inhibitors target two of the
central balances governing tumour growth and metastasis, namely
angiogenesis and apoptosis. In this study for all parameters studied,
the selective COX-2 inhibitor, SC-236, was as effective as the non-
selective inhibitor, indomethacin, at the doses examined, suggesting
that the anti-tumour effects observed herein with indomethacin,
are primarily due to the inhibition of COX-2. This suggests that
selective COX-2 inhibition may be as effective as the non-selective
NSAIDs with the distinct advantage of a low toxicity profile
(Hawkey, 1999, Masferrer et al, 2000). The anti-angiogenic and
pro-apoptotic properties of COX inhibitors, suggest that these
drugs may increase the anti-tumour effects of conventional
chemotherapy and radiotherapy used in the treatment of breast
cancer. Indeed, SC-236 has been shown to increase radiosensitivity
in a murine sarcoma model (Milas et al, 1999).
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